Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab
Key facts
- Who runs it
- University Hospital, Caen
- Where
- France and Guadeloupe25 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 450 people, planned
- Starts
- 15 Jan 2027
- Expected to end
- 30 Jun 2028
- Type of study
- Observational, 2 groups
- Record updated
- 18 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- For autonomous adult patients (patient enrolled in the study):
- Adult patient (>= 18 years old) with severe or moderate hemophilia A
- Receiving prophylactic treatment with emicizumab for more than 1 year
- Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Patient non-opposition obtained; For autonomous pediatric/minor patients (patient enrolled in the study):
- Minor patient (< 18 years old) with severe or moderate hemophilia A
- Receiving prophylactic treatment with emicizumab for more than 1 year
- Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Patient non-opposition obtained
- Non-opposition obtained from parents or legal guardians; For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):
- Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
- Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
- Parent caregiver non-opposition obtained; For healthcare providers:
- Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
- Healthcare provider non-opposition obtained
Who cannot take part
- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation; For autonomous pediatric/minor patients:
- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation; For non-autonomous pediatric/minor patients:
- For autonomous adult patients:
- Parent caregiver who is a healthcare professional
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.
Read full original descriptionShow less
Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.
The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.
The 2 groups in the trial
- Patients or Family Caregivers
Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy
- Healthcare Providers
Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis
- Record updated
- 18 November 2026